Latest News by Industry
![Lyell Immunopharma, Inc. [LYEL] reports annual net loss of $234,632,000.0](/_next/image?url=https%3A%2F%2F10kinfo-appdata.s3.us-west-2.amazonaws.com%2Fedgar0105%2FCompanyLogos%2FUS%2FLYEL.png&w=1200&q=75)
Lyell Immunopharma, Inc. [LYEL] has reported a net loss of $234,632,000.0 for year ended Dec 31, 2023.
The Company said in a filing before the Securities and Exchange Commission that its total revenue for the year was $130.0 thousand
Based in SOUTH SAN FRANCISCO, California, Lyell Immunopharma, Inc. operates in the MANUFACTURING sector.
In the latest annual report for the year ended December 31, 2023, the company reported robust revenues of $130 million, showing a significant increase from $84.7 million in the previous year and $10.7 million in 2021.
The cost of goods sold or operating expenses for the year included research and development expenses of $182.9 million, general and administrative expenses of $67 million, and other operating income of $(2.8) million. These figures were lower than the previous year's expenses of $159.2 million, $117.3 million, and $(4.8) million respectively, suggesting operational cost efficiencies.
The net income for the year is reported as a loss of $234.6 million, a wider loss compared to $183.1 million in the previous year and $250.2 million in 2021.
Earnings per share for basic and diluted amounts also reflect the negative trend, with a loss per share of $(0.93) compared to $(0.74) in the previous year and $(1.84) in 2021.
Overall, the company's financial performance indicates challenges in managing operational expenses and generating profits, as evidenced by the widening net loss and negative earnings per share figures.